Difference between revisions of "Pamidronate (Aredia)"
m |
m |
||
Line 8: | Line 8: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.uptodate.com/contents/pamidronate-patient-drug-information Pamidronate (Aredia) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/pamidronate-patient-drug-information Pamidronate (Aredia) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/pamidronate-patient-drug-information Pamidronate (Aredia) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/pamidronate-patient-drug-information Pamidronate (Aredia) patient drug information (UpToDate)]</ref> | ||
+ | |||
+ | ==History of changes in FDA indication== | ||
+ | * 10/31/1991: Initial FDA approval | ||
==Also known as== | ==Also known as== | ||
Line 15: | Line 18: | ||
<references/> | <references/> | ||
+ | [[Category:Drug index]] | ||
[[Category:Bisphosphonates]] | [[Category:Bisphosphonates]] | ||
+ | |||
+ | [[Category:Drugs FDA approved in 1991]] |
Revision as of 20:37, 25 October 2014
General information
Class/mechanism: Bisphosphonate, inhibits osteoclast activity and bone resorption. Exact mechanism not understood, but is believed to also involve blocking dissolution of bone calcium phosphate (hydroxyapatite) crystals.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
History of changes in FDA indication
- 10/31/1991: Initial FDA approval
Also known as
pamidronate disodium omega, Pamisol, PMS-pamidronate, or Rhoxal-pamidronate.